share_log

HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9

HC Wainwright & Co.維持對MinK Therapeutics的買入,將目標股價下調至9美元
Moomoo 24/7 ·  03/21 11:27

HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics (NASDAQ:INKT) with a Buy and lowers the price target from $10 to $9.

HC Wainwright & Co. 分析師艾米麗·博德納爾維持MinK Therapeutics(納斯達克股票代碼:INKT)的買入並將目標股價從10美元下調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論